Newstral
AstraZeneca PLC
- AstraZeneca says key lung cancer drug improved survival - Fri, 05 Apr 2024 PSTsyndication.washingtonpost.com
- MSell AstraZeneca, says UBS, which upgrades European rivals including GSK1 min readmarketwatch.com
- Merck to pay as much as $22 billion for Daiichi Sankyo's cancer drugs - Fri, 20 Oct 2023 PSTsyndication.washingtonpost.com
- BA new era of books helps Black workers navigate corporate Americabloomberg.com
- MAstraZeneca says cancer drug Enhertu showed positive results1 min readmarketwatch.com
- MAstraZeneca says Forxiga approved in EU for heart failure1 min readmarketwatch.com
- This 7.9% Dividend Is Built For Whatever Comes Our Way In ’23Forbes
- Live: 'Covid variant likely resistant to AstraZeneca antibody drug'The Times of India
- MAstraZeneca's Forxiga gets EU approval recommendation for symptomatic chronic heart failure1 min readmarketwatch.com
- MAstraZeneca's Imfinzi plus Imjudo recommended for approval in the EU1 min readmarketwatch.com
- MWHO says 90% decline in COVID deaths since Feb. is 'cause for optimism,' while urging vigilance against new variants4 min readmarketwatch.com
- MAstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints1 min readmarketwatch.com
- Americans could have to pay for COVID shots starting next yearstaradvertiser.com
- MEnhertu significantly delayed breast cancer progression in trial, AstraZeneca says1 min readmarketwatch.com
- GNT 3 Growth Factor Receptor Market Jump on Biggest Revenue Growth | , Array BioPharma Inc, AstraZeneca Plc, Daiichi Sankyo Company Ltd, Handok Inc, Ignyta Inc, Loxo Oncology Inc, Netris Pharma SAS, Plexxikon Inc,galleonnews.com
- MAstraZeneca Enhertu breast cancer drug is recommended for EU approval1 min readmarketwatch.com
- GSquamous Non-Small Cell Lung Cancer Therapeutics Market, Global Outlook and Forecast 2022-2028galleonnews.com
- GLeukotriene Modifiers Market, Global Outlook and Forecast 2022-2028galleonnews.com
- Gordon Pape: Health care, consumer staples ETFs could be solid additions to a defensive portfolioThe Globe and Mail
- MAstraZeneca's Covid-19 vaccine gets EU approval for third doses1 min readmarketwatch.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.